Loading…
Safety evaluation of a recombinant myxoma-RHDV virus inducing horizontal transmissible protection against myxomatosis and rabbit haemorrhagic disease
We have recently developed a transmissible vaccine to immunize rabbits against myxomatosis and rabbit haemorrhagic disease based on a recombinant myxoma virus (MV) expressing the rabbit haemorrhagic disease virus (RHDV) capsid protein [Bárcena et al. Horizontal transmissible protection against myxom...
Saved in:
| Published in: | Vaccine 2000-09, Vol.19 (2), p.174-182 |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c523t-b857f056117fbe6f499911e156f20dea9166cf68901984a3d23964d6084d48863 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c523t-b857f056117fbe6f499911e156f20dea9166cf68901984a3d23964d6084d48863 |
| container_end_page | 182 |
| container_issue | 2 |
| container_start_page | 174 |
| container_title | Vaccine |
| container_volume | 19 |
| creator | Torres, Juan M Ramı́rez, Miguel A Morales, Mónica Bárcena, Juan Vázquez, Belén Espuña, Enric Pagès-Manté, Albert Sánchez-Vizcaı́no, José M |
| description | We have recently developed a transmissible vaccine to immunize rabbits against myxomatosis and rabbit haemorrhagic disease based on a recombinant myxoma virus (MV) expressing the rabbit haemorrhagic disease virus (RHDV) capsid protein [Bárcena et al. Horizontal transmissible protection against myxomatosis and rabbit haemorragic disease using a recombinant myxoma virus. J. Virol. 2000;74:1114–23]. Administration of the recombinant virus protects rabbits against lethal RHDV and MV challenges. Furthermore, the recombinant virus is capable of horizontal spreading promoting protection of contact animals, thus providing the opportunity to immunize wild rabbit populations. However, potential risks must be extensively evaluated before considering its field use. In this study several safety issues concerning the proposed vaccine have been evaluated under laboratory conditions. Results indicated that vaccine administration is safe even at a 100-fold overdose. No undesirable effects were detected upon administration to immunosuppressed or pregnant rabbits. The recombinant virus maintained its attenuated phenotype after 10 passages in vivo. |
| doi_str_mv | 10.1016/S0264-410X(00)00183-3 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7125741</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X00001833</els_id><sourcerecordid>17623299</sourcerecordid><originalsourceid>FETCH-LOGICAL-c523t-b857f056117fbe6f499911e156f20dea9166cf68901984a3d23964d6084d48863</originalsourceid><addsrcrecordid>eNqFks9u1DAQhyMEotvCI4B8QAgOgXHsOPEFhMqfIlVCooC4WRPH2TVK7MV2Vl3eg_fF3V1KOfXkg7_5aWa-KYpHFF5QoOLlBVSCl5zC92cAzwFoy0p2p1jQtmFlVdP2brG4Ro6K4xh_AEDNqLxfHFGQDEQDi-L3BQ4mbYnZ4Dhjst4RPxAkwWg_ddahS2TaXvoJy89nb7-RjQ1zJNb1s7ZuSVY-2F_eJRxJCujiZGO03WjIOvhk9C4Pl2hd_BuTfLSRoOtJwK6ziazQTD6EFS6tJr2NBqN5UNwbcIzm4eE9Kb6-f_fl9Kw8__Th4-mb81LXFUtl19bNALWgtBk6IwYupaTU0FoMFfQGJRVCD6KVQGXLkfUVk4L3Alre87YV7KR4tc9dz91kem1cnmJU62AnDFvl0ar_f5xdqaXfqIZWdcNpDnh6CAj-52xiUnkD2owjOuPnmLmm5rTit4K0ERWrpMxgvQd18DEGM1x3Q0FdmVc78-pKqwJQO_OK5brHN0e5UbVXnYEnBwCjxnHIurSN_7gaOG-qjL3eYybvfWNNUFFb47Tpbb6JpHpvb-nkD0mIzvk</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17623299</pqid></control><display><type>article</type><title>Safety evaluation of a recombinant myxoma-RHDV virus inducing horizontal transmissible protection against myxomatosis and rabbit haemorrhagic disease</title><source>ScienceDirect Freedom Collection 2022-2024</source><creator>Torres, Juan M ; Ramı́rez, Miguel A ; Morales, Mónica ; Bárcena, Juan ; Vázquez, Belén ; Espuña, Enric ; Pagès-Manté, Albert ; Sánchez-Vizcaı́no, José M</creator><creatorcontrib>Torres, Juan M ; Ramı́rez, Miguel A ; Morales, Mónica ; Bárcena, Juan ; Vázquez, Belén ; Espuña, Enric ; Pagès-Manté, Albert ; Sánchez-Vizcaı́no, José M</creatorcontrib><description>We have recently developed a transmissible vaccine to immunize rabbits against myxomatosis and rabbit haemorrhagic disease based on a recombinant myxoma virus (MV) expressing the rabbit haemorrhagic disease virus (RHDV) capsid protein [Bárcena et al. Horizontal transmissible protection against myxomatosis and rabbit haemorragic disease using a recombinant myxoma virus. J. Virol. 2000;74:1114–23]. Administration of the recombinant virus protects rabbits against lethal RHDV and MV challenges. Furthermore, the recombinant virus is capable of horizontal spreading promoting protection of contact animals, thus providing the opportunity to immunize wild rabbit populations. However, potential risks must be extensively evaluated before considering its field use. In this study several safety issues concerning the proposed vaccine have been evaluated under laboratory conditions. Results indicated that vaccine administration is safe even at a 100-fold overdose. No undesirable effects were detected upon administration to immunosuppressed or pregnant rabbits. The recombinant virus maintained its attenuated phenotype after 10 passages in vivo.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/S0264-410X(00)00183-3</identifier><identifier>PMID: 10930670</identifier><identifier>CODEN: VACCDE</identifier><language>eng</language><publisher>Oxford: Elsevier Ltd</publisher><subject>Animals ; Biological and medical sciences ; Caliciviridae Infections - prevention & control ; Female ; Fundamental and applied biological sciences. Psychology ; Hemorrhagic Disease Virus, Rabbit - immunology ; Immunization ; Immunosuppression ; Microbiology ; myxoma virus ; Myxoma-RHDV ; Myxomatosis, Infectious - prevention & control ; Pregnancy ; rabbit hemorrhagic disease ; Rabbit hemorrhagic disease virus ; Rabbits ; Safety ; Transmissible vaccine ; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies ; Vaccines, Synthetic - adverse effects ; Viral Vaccines - adverse effects ; Virology</subject><ispartof>Vaccine, 2000-09, Vol.19 (2), p.174-182</ispartof><rights>2000 Elsevier Science Ltd</rights><rights>2000 INIST-CNRS</rights><rights>Copyright © 2000 Elsevier Science Ltd. All rights reserved. 2000 Elsevier Science Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c523t-b857f056117fbe6f499911e156f20dea9166cf68901984a3d23964d6084d48863</citedby><cites>FETCH-LOGICAL-c523t-b857f056117fbe6f499911e156f20dea9166cf68901984a3d23964d6084d48863</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1504472$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10930670$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Torres, Juan M</creatorcontrib><creatorcontrib>Ramı́rez, Miguel A</creatorcontrib><creatorcontrib>Morales, Mónica</creatorcontrib><creatorcontrib>Bárcena, Juan</creatorcontrib><creatorcontrib>Vázquez, Belén</creatorcontrib><creatorcontrib>Espuña, Enric</creatorcontrib><creatorcontrib>Pagès-Manté, Albert</creatorcontrib><creatorcontrib>Sánchez-Vizcaı́no, José M</creatorcontrib><title>Safety evaluation of a recombinant myxoma-RHDV virus inducing horizontal transmissible protection against myxomatosis and rabbit haemorrhagic disease</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>We have recently developed a transmissible vaccine to immunize rabbits against myxomatosis and rabbit haemorrhagic disease based on a recombinant myxoma virus (MV) expressing the rabbit haemorrhagic disease virus (RHDV) capsid protein [Bárcena et al. Horizontal transmissible protection against myxomatosis and rabbit haemorragic disease using a recombinant myxoma virus. J. Virol. 2000;74:1114–23]. Administration of the recombinant virus protects rabbits against lethal RHDV and MV challenges. Furthermore, the recombinant virus is capable of horizontal spreading promoting protection of contact animals, thus providing the opportunity to immunize wild rabbit populations. However, potential risks must be extensively evaluated before considering its field use. In this study several safety issues concerning the proposed vaccine have been evaluated under laboratory conditions. Results indicated that vaccine administration is safe even at a 100-fold overdose. No undesirable effects were detected upon administration to immunosuppressed or pregnant rabbits. The recombinant virus maintained its attenuated phenotype after 10 passages in vivo.</description><subject>Animals</subject><subject>Biological and medical sciences</subject><subject>Caliciviridae Infections - prevention & control</subject><subject>Female</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Hemorrhagic Disease Virus, Rabbit - immunology</subject><subject>Immunization</subject><subject>Immunosuppression</subject><subject>Microbiology</subject><subject>myxoma virus</subject><subject>Myxoma-RHDV</subject><subject>Myxomatosis, Infectious - prevention & control</subject><subject>Pregnancy</subject><subject>rabbit hemorrhagic disease</subject><subject>Rabbit hemorrhagic disease virus</subject><subject>Rabbits</subject><subject>Safety</subject><subject>Transmissible vaccine</subject><subject>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies</subject><subject>Vaccines, Synthetic - adverse effects</subject><subject>Viral Vaccines - adverse effects</subject><subject>Virology</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><recordid>eNqFks9u1DAQhyMEotvCI4B8QAgOgXHsOPEFhMqfIlVCooC4WRPH2TVK7MV2Vl3eg_fF3V1KOfXkg7_5aWa-KYpHFF5QoOLlBVSCl5zC92cAzwFoy0p2p1jQtmFlVdP2brG4Ro6K4xh_AEDNqLxfHFGQDEQDi-L3BQ4mbYnZ4Dhjst4RPxAkwWg_ddahS2TaXvoJy89nb7-RjQ1zJNb1s7ZuSVY-2F_eJRxJCujiZGO03WjIOvhk9C4Pl2hd_BuTfLSRoOtJwK6ziazQTD6EFS6tJr2NBqN5UNwbcIzm4eE9Kb6-f_fl9Kw8__Th4-mb81LXFUtl19bNALWgtBk6IwYupaTU0FoMFfQGJRVCD6KVQGXLkfUVk4L3Alre87YV7KR4tc9dz91kem1cnmJU62AnDFvl0ar_f5xdqaXfqIZWdcNpDnh6CAj-52xiUnkD2owjOuPnmLmm5rTit4K0ERWrpMxgvQd18DEGM1x3Q0FdmVc78-pKqwJQO_OK5brHN0e5UbVXnYEnBwCjxnHIurSN_7gaOG-qjL3eYybvfWNNUFFb47Tpbb6JpHpvb-nkD0mIzvk</recordid><startdate>20000915</startdate><enddate>20000915</enddate><creator>Torres, Juan M</creator><creator>Ramı́rez, Miguel A</creator><creator>Morales, Mónica</creator><creator>Bárcena, Juan</creator><creator>Vázquez, Belén</creator><creator>Espuña, Enric</creator><creator>Pagès-Manté, Albert</creator><creator>Sánchez-Vizcaı́no, José M</creator><general>Elsevier Ltd</general><general>Elsevier</general><general>Elsevier Science Ltd</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7T7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20000915</creationdate><title>Safety evaluation of a recombinant myxoma-RHDV virus inducing horizontal transmissible protection against myxomatosis and rabbit haemorrhagic disease</title><author>Torres, Juan M ; Ramı́rez, Miguel A ; Morales, Mónica ; Bárcena, Juan ; Vázquez, Belén ; Espuña, Enric ; Pagès-Manté, Albert ; Sánchez-Vizcaı́no, José M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c523t-b857f056117fbe6f499911e156f20dea9166cf68901984a3d23964d6084d48863</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Animals</topic><topic>Biological and medical sciences</topic><topic>Caliciviridae Infections - prevention & control</topic><topic>Female</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Hemorrhagic Disease Virus, Rabbit - immunology</topic><topic>Immunization</topic><topic>Immunosuppression</topic><topic>Microbiology</topic><topic>myxoma virus</topic><topic>Myxoma-RHDV</topic><topic>Myxomatosis, Infectious - prevention & control</topic><topic>Pregnancy</topic><topic>rabbit hemorrhagic disease</topic><topic>Rabbit hemorrhagic disease virus</topic><topic>Rabbits</topic><topic>Safety</topic><topic>Transmissible vaccine</topic><topic>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies</topic><topic>Vaccines, Synthetic - adverse effects</topic><topic>Viral Vaccines - adverse effects</topic><topic>Virology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Torres, Juan M</creatorcontrib><creatorcontrib>Ramı́rez, Miguel A</creatorcontrib><creatorcontrib>Morales, Mónica</creatorcontrib><creatorcontrib>Bárcena, Juan</creatorcontrib><creatorcontrib>Vázquez, Belén</creatorcontrib><creatorcontrib>Espuña, Enric</creatorcontrib><creatorcontrib>Pagès-Manté, Albert</creatorcontrib><creatorcontrib>Sánchez-Vizcaı́no, José M</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Torres, Juan M</au><au>Ramı́rez, Miguel A</au><au>Morales, Mónica</au><au>Bárcena, Juan</au><au>Vázquez, Belén</au><au>Espuña, Enric</au><au>Pagès-Manté, Albert</au><au>Sánchez-Vizcaı́no, José M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Safety evaluation of a recombinant myxoma-RHDV virus inducing horizontal transmissible protection against myxomatosis and rabbit haemorrhagic disease</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2000-09-15</date><risdate>2000</risdate><volume>19</volume><issue>2</issue><spage>174</spage><epage>182</epage><pages>174-182</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><coden>VACCDE</coden><abstract>We have recently developed a transmissible vaccine to immunize rabbits against myxomatosis and rabbit haemorrhagic disease based on a recombinant myxoma virus (MV) expressing the rabbit haemorrhagic disease virus (RHDV) capsid protein [Bárcena et al. Horizontal transmissible protection against myxomatosis and rabbit haemorragic disease using a recombinant myxoma virus. J. Virol. 2000;74:1114–23]. Administration of the recombinant virus protects rabbits against lethal RHDV and MV challenges. Furthermore, the recombinant virus is capable of horizontal spreading promoting protection of contact animals, thus providing the opportunity to immunize wild rabbit populations. However, potential risks must be extensively evaluated before considering its field use. In this study several safety issues concerning the proposed vaccine have been evaluated under laboratory conditions. Results indicated that vaccine administration is safe even at a 100-fold overdose. No undesirable effects were detected upon administration to immunosuppressed or pregnant rabbits. The recombinant virus maintained its attenuated phenotype after 10 passages in vivo.</abstract><cop>Oxford</cop><pub>Elsevier Ltd</pub><pmid>10930670</pmid><doi>10.1016/S0264-410X(00)00183-3</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0264-410X |
| ispartof | Vaccine, 2000-09, Vol.19 (2), p.174-182 |
| issn | 0264-410X 1873-2518 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7125741 |
| source | ScienceDirect Freedom Collection 2022-2024 |
| subjects | Animals Biological and medical sciences Caliciviridae Infections - prevention & control Female Fundamental and applied biological sciences. Psychology Hemorrhagic Disease Virus, Rabbit - immunology Immunization Immunosuppression Microbiology myxoma virus Myxoma-RHDV Myxomatosis, Infectious - prevention & control Pregnancy rabbit hemorrhagic disease Rabbit hemorrhagic disease virus Rabbits Safety Transmissible vaccine Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies Vaccines, Synthetic - adverse effects Viral Vaccines - adverse effects Virology |
| title | Safety evaluation of a recombinant myxoma-RHDV virus inducing horizontal transmissible protection against myxomatosis and rabbit haemorrhagic disease |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T20%3A17%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Safety%20evaluation%20of%20a%20recombinant%20myxoma-RHDV%20virus%20inducing%20horizontal%20transmissible%20protection%20against%20myxomatosis%20and%20rabbit%20haemorrhagic%20disease&rft.jtitle=Vaccine&rft.au=Torres,%20Juan%20M&rft.date=2000-09-15&rft.volume=19&rft.issue=2&rft.spage=174&rft.epage=182&rft.pages=174-182&rft.issn=0264-410X&rft.eissn=1873-2518&rft.coden=VACCDE&rft_id=info:doi/10.1016/S0264-410X(00)00183-3&rft_dat=%3Cproquest_pubme%3E17623299%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c523t-b857f056117fbe6f499911e156f20dea9166cf68901984a3d23964d6084d48863%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=17623299&rft_id=info:pmid/10930670&rfr_iscdi=true |